These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 28855206)

  • 21. Plasma cell dynamics in the bone marrow niche.
    Benet Z; Jing Z; Fooksman DR
    Cell Rep; 2021 Feb; 34(6):108733. PubMed ID: 33567286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The CXCL12-3'A allele plays a favourable role in patients with multiple myeloma.
    Mazur G; Gębura K; Gieryng A; Butrym A; Wróbel T; Bogunia-Kubik K
    Cytokine; 2013 Oct; 64(1):422-6. PubMed ID: 23711392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies.
    Peled A; Klein S; Beider K; Burger JA; Abraham M
    Cytokine; 2018 Sep; 109():11-16. PubMed ID: 29903571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression and function of chemokine receptors in human multiple myeloma.
    Möller C; Strömberg T; Juremalm M; Nilsson K; Nilsson G
    Leukemia; 2003 Jan; 17(1):203-10. PubMed ID: 12529679
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Sphingosine-1-Phosphate Modulator FTY720 Targets Multiple Myeloma via the CXCR4/CXCL12 Pathway.
    Beider K; Rosenberg E; Bitner H; Shimoni A; Leiba M; Koren-Michowitz M; Ribakovsky E; Klein S; Olam D; Weiss L; Wald H; Abraham M; Galun E; Peled A; Nagler A
    Clin Cancer Res; 2017 Apr; 23(7):1733-1747. PubMed ID: 27697999
    [No Abstract]   [Full Text] [Related]  

  • 26. Rac1 plays a role in CXCL12 but not CCL3-induced chemotaxis and Rac1 GEF inhibitor NSC23766 has off target effects on CXCR4.
    Mills SC; Howell L; Beekman A; Stokes L; Mueller A
    Cell Signal; 2018 Jan; 42():88-96. PubMed ID: 29050986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CXCL12/CXCR4 axis in tissue targeting and bone destruction in cancer and multiple myeloma.
    Ooi LL; Dunstan CR
    J Bone Miner Res; 2009 Jul; 24(7):1147-9. PubMed ID: 19419311
    [No Abstract]   [Full Text] [Related]  

  • 28. [SDF-1/CXCR4 and multiple myeloma osteolytic bone lesions--review].
    Bao L; Huang XJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr; 16(2):442-6. PubMed ID: 18426683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting SDF-1 in multiple myeloma tumor microenvironment.
    Bouyssou JM; Ghobrial IM; Roccaro AM
    Cancer Lett; 2016 Sep; 380(1):315-8. PubMed ID: 26655999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effect of CCL3 on osteoblast in myeloma bone disease].
    Zhao S; Fu R; Liu H; Wang Y; Li L; Liu C; Zhang T; Ding S; Gao S; Ruan E; Qu W; Wang H; Wang X; Wu Y; Song J; Liu H; Guan J; Shao Z
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jul; 35(7):623-7. PubMed ID: 25052606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients.
    Zannettino AC; Farrugia AN; Kortesidis A; Manavis J; To LB; Martin SK; Diamond P; Tamamura H; Lapidot T; Fujii N; Gronthos S
    Cancer Res; 2005 Mar; 65(5):1700-9. PubMed ID: 15753365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrin alpha4beta1 involvement in stromal cell-derived factor-1alpha-promoted myeloma cell transendothelial migration and adhesion: role of cAMP and the actin cytoskeleton in adhesion.
    Parmo-Cabañas M; Bartolomé RA; Wright N; Hidalgo A; Drager AM; Teixidó J
    Exp Cell Res; 2004 Apr; 294(2):571-80. PubMed ID: 15023543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The stromal derived factor-1\CXCR4 axis--a legitimate therapeutic target in multiple myeloma?
    Katz BZ; Tavor S
    Leuk Lymphoma; 2009 Jul; 50(7):1067-8. PubMed ID: 19557626
    [No Abstract]   [Full Text] [Related]  

  • 34. Immature dendritic cells from patients with multiple myeloma are prone to osteoclast differentiation in vitro.
    Tucci M; Ciavarella S; Strippoli S; Brunetti O; Dammacco F; Silvestris F
    Exp Hematol; 2011 Jul; 39(7):773-83.e1. PubMed ID: 21569821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CXCR4 is a good survival prognostic indicator in multiple myeloma patients.
    Bao L; Lai Y; Liu Y; Qin Y; Zhao X; Lu X; Jiang Q; Lu J; Huang X
    Leuk Res; 2013 Sep; 37(9):1083-8. PubMed ID: 23849988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The involvement of stromal derived factor 1alpha in homing and progression of multiple myeloma in the 5TMM model.
    Menu E; Asosingh K; Indraccolo S; De Raeve H; Van Riet I; Van Valckenborgh E; Vande Broek I; Fujii N; Tamamura H; Van Camp B; Vanderkerken K
    Haematologica; 2006 May; 91(5):605-12. PubMed ID: 16627256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CCR1 as a target for multiple myeloma.
    Vallet S; Anderson KC
    Expert Opin Ther Targets; 2011 Sep; 15(9):1037-47. PubMed ID: 21609295
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment.
    Borsi E; Perrone G; Terragna C; Martello M; Zamagni E; Tacchetti P; Pantani L; Brioli A; Dico AF; Zannetti BA; Rocchi S; Cavo M
    Exp Cell Res; 2014 Nov; 328(2):444-55. PubMed ID: 25257607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Correlation between Expression of CXCL12, CXCR4, VEGF, MVD and Prognosis in Patients with Multiple Myeloma].
    Zhang K; Zhou J; Li XM; Huang CL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1962-1971. PubMed ID: 33283727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
    Yu X; Huang Y; Collin-Osdoby P; Osdoby P
    J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.